Tinoridine

Summary

Tinoridine (CHEMBL592943) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 316.4 Da · C17H20N2O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL592943
Name	Tinoridine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5480
Molecular formula	C17H20N2O2S
Molecular weight	316.4
InChIKey	PFENFDGYVLAFBR-UHFFFAOYSA-N

SMILES: CCOC(=O)C1=C(SC2=C1CCN(C2)CC3=CC=CC=C3)N

IUPAC name: ethyl 2-amino-6-benzyl-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxylate

Also known as: NSC-158555, Tinoridina, Tinoridine, Y 3642, Y-3642, SID17441321, SID29215397, SID124892200, SID144205231, TINORIDINE, SID170465864

Parent form; salt/anhydrous children: CHEMBL4303244

Patent coverage: 836 distinct patent families (3,303 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Microtubule-associated protein tau, Fructose-bisphosphate aldolase, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Menin/Histone-lysine N-methyltransferase MLL, Adenosine receptor A1, Cruzipain.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 9 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q9F4F7	5	Potency	10000	nM	CHEMBL_ACT_4373363
MAPT	5	Potency	10000	nM	CHEMBL_ACT_4506765

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01224756	PHASE4	COMPLETED	Efficacy of Tinoridine in Treating Pain and Inflammation in Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).